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Abstract
AIM: To investigate the combined diagnostic accuracy 
of acoustic radiation force impulse (ARFI), aspartate 
aminotransferase to platelet ratio index (APRI) and 
Forns index for a non-invasive assessment of liver 
fibrosis in patients with chronic hepatitis B (CHB). 
METHODS: In this prospective study, 206 patients 
had CHB with liver fibrosis stages F0-F4 classified 
by METAVIR and 40 were healthy volunteers were 
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measured by ARFI, APRI and Forns index separately or 
combined as indicated. 
RESULTS: ARFI, APRI or Forns index demonstrated 
a significant correlation with the histological stage 
(all P  < 0.001). According to the AUROC of ARFI and 
APRI for evaluating fibrotic stages more than F2, ARFI 
showed an enhanced diagnostic accuracy than APRI 
(P  < 0.05). The combined measurement of ARFI and 
APRI exhibited better accuracy than ARFI alone when 
evaluating ≥ F2 fibrotic stage (Z = 2.77, P  = 0.006). 
Combination of ARFI, APRI and Forns index did not 
obviously improve the diagnostic accuracy compared 
to the combination of ARFI and APRI (Z = 0.958, P  = 
0.338). 
CONCLUSION: ARFI + APRI showed enhanced dia-
gnostic accuracy than ARFI or APRI alone for significant 
liver fibrosis and ARFI + APRI + Forns index shows the 
same effect with ARFI + APRI. 
Key words: Acoustic radiation force impulse; Aspartate 
aminotransferase to platelet ratio index; Forns index; 
Hepatitis B virus; Non-invasive diagnosis
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Core tip: Chronic hepatitis B (CHB) is a major health 
problem in a lot of countries all over the world, parti-
cularly in China. An accurate staging of liver fibrosis 
is critical for prognosticating this disease. However, 
although it is still the golden standard, liver biopsy 
is hindered by its inherent drawbacks in clinical appli-
cations. In this study, we demonstrated that non-
invasive methods, including acoustic radiation force 
impulse (ARFI), aspartate aminotransferase to platelet 
ratio index (APRI) and Forns index showed significant 
correlations with the histological staging results from 
liver biopsy. The combined measurement of ARFI and 
APRI had the best diagnostic accuracy, which provided 
an ideal and convenient non-invasive diagnostic method 
for the detection of hepatic fibrosis of CHB patients in 
clinical practice.
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INTRODUCTION
Chronic liver injury, such as chronic hepatitis B (CHB), 
may cause inflammation and necrosis of hepatocytes, 
leading to hepatic fibrosis. It is a long-term patho-
logical change with certain possibility (about 20%) 
of progressing to liver cirrhosis[1]. Unlike cirrhosis, 
hepatic fibrosis is reversible at its early stage when 
proper clinical therapeutic interventions are applied[2]. 
Therefore, an accurate staging of liver fibrosis is critical 
for prognosticating this disease. To date, the gold 
standard for staging hepatic fibrosis is still the liver 
biopsy, which cannot be routinely performed because 
of its inherent limitations, such as pain, bleeding, 
inaccurate staging from sampling error, and variability 
of biopsy interpretation[3]. During the past decades, 
considerable efforts have been invested in developing 
non-invasive methods of assessments, which may 
provide accurate evaluation of liver fibrosis comparable 
to liver biopsy. Indeed, these non-invasive methods have 
several advantages such as high safety margin, simple, 
convenient, reproducible, and inexpensive.
Acoustic radiation force impulse (ARFI) is a new 
quantitative assessment method of estimating tissue 
stiffness through measurement of shear wave velocity 
(SWV, measured in m/s). Its quantitative representation 
is named as virtual touch tissue quantification, which 
gives an objective numerical evaluation of the tissue 
stiffness[4-6]. ARFI imaging offers a quantitative assess-
ment of the hepatic parenchyma elasticity to non-
invasively grade and stage hepatic fibrosis. It has been 
used to diagnose hepatic fibrosis of patients with CHB[7], 
hepatitis C[8], cirrhosis[9], and non-alcoholic fatty liver 
disease (NAFLD)[10]. In addition, ARFI is often perfor-
med with serum liver functions tests [e.g., alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), total proteins, and albumin] to generate better 
prediction and evaluation of liver fibrosis[11]. Among 
these, AST platelet ratio (APRI) is a serum hepatic 
function test which has been proposed as a non-invasive 
tool for the assessment of liver fibrosis in CHB[12] or 
chronic hepatitis C[13]. Another important serum test 
is Forns index method, which uses simple obtained 
parameters including age, gamma-glutamyltransferase 
(GGT), cholesterol, and platelet count (PLT), but it 
requires a relatively complicated calculation[14]. One of the 
advantages of APRI and Forns index over the other non-
invasive tests is that they are based on readily available 
blood tests and simple to use. Although these strategies 
have been widely applied in the past decade for hepatitis 
C evaluation[15,16], their accuracy for CHB grading are still 
not comparable with liver biopsy. Therefore, a combined 
use of these non-invasive methods may be another 
promising and practical diagnostic application in CHB 
patients. In the current study, we aimed to compare 
the accuracy among ARFI, APRI, Forns index and their 
combinations for non-invasive diagnosis grading and 
prognosis of human CHB-induced hepatic fibrosis.
MATERIALS AND METHODS
Subjects of study
This prospective study was approved by the ethical 
committee of Shenzhen Third People’s Hospital. All 
study procedures and methods were in accordance with 
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the approved guidelines. All patients in this study were 
fully informed about the research protocol including the 
data handling and the privacy of personal data. After 
this procedure, patients signed the written consent. 
A total of 246 subjects were consecutively enrolled in 
this study, including 206 CHB subjects and 40 healthy 
subjects. These 206 CHB cases were selected from 245 
CHB patients diagnosed by liver biopsy in Shenzhen 
Third People’s Hospital, from May 2011 to December 
2014. Of the 206 CHB patients, there were 39 female 
cases (18.9%) and 167 male cases (81.1%). Inclusion 
criteria are: (1) patients must be 18-65 years old; (2) 
with hepatitis B surface antigen positive for more than 6 
mo; (3) without receiving antiviral treatment before this 
study; (4) ALT and AST were < 2 × upper limit of normal 
(ULN) in the past 6 mo; (5) 18.5 < body mass index 
(BMI) < 31.0; (6) length of liver biopsy tissue ≥ 15 mm 
and contains at least 10 periportal areas; (7) hemoglobin 
> 90 g/L, prothrombin time 11-15.1 s; (8) activated 
partial thromboplastin time and thrombin time were at a 
normal range; and (9) cardiac and renal functions were 
normal. Negative for the following: Human immuno-
deficiency virus, hepatitis A virus, hepatitis C virus (HCV), 
hepatitis D virus, hepatitis E virus super-infection or co-
infection, auto-immune liver diseases, alcoholic steatosis, 
NAFLD, hepatocellular carcinoma (HCC), pregnancy, 
ascites, as well as jaundice. Of the 245 eligible CHB 
patients, 39 were excluded because of the following: 
NAFLD (n = 10), received antiviral treatment before this 
study (n = 8), jaundice (n = 5), alcoholic steatosis (n = 
6), HCV infection (n = 2), auto-immune liver disease (n 
= 1), with age < 18 (n = 4), with age > 65 (n = 1), and 
declined to participate (n = 2). Healthy group consisted 
of 40 volunteers, with 30 males and 10 females, aged 
range from 20-53 years old, with mean age of 39.8 
± 11.45 years and no hepatitis B virus (HBV) or HCV 
infection, no hypertension, diabetes, fatty liver and other 
apparent diseases. The BMI of healthy subjects were 
between 18.5 and 31.0. Other parameters were similar 
to the CHB patients. All CHB patients were examined 
by ARFI one day before or on the day of liver biopsy. All 
the subjects had blood or sera drawn for the detection of 
platelet and fibrotic serological markers.
Liver biopsy and pathological staging
Liver biopsy tissue specimens were collected by needle 
puncture (MN1613, Bard Biopsy Systems, Tempe, 
AZ) under the Color Doppler Ultrasound guidance in 
a separate clinic setting for diagnostic purposes. The 
liver specimen was 15-20 mm in length, including at 
least 10 portal vein areas. Then it was embedded by 
paraffin and stained by Sirius Red (Sigma-Aldrich, 
St. Louis, MO). Liver fibrosis stage was assessed by 
the METAVIR scoring system (F0 = no fibrosis; F1 = 
portal fibrosis without septa; F2 = portal fibrosis and 
a few septa; F3 = numerous fibrosis without cirrhosis; 
and F4 = cirrhosis)[17]. The METAVIR scoring system 
was previously used in other reports on CHB[18,19]. Two 
independent pathologists were responsible for the 
staging of all samples without additional information 
about the specimens they checked.
ARFI
The detection of ARFI in the liver was performed under 
fasting conditions using Siemens Acuson S2000 with 
probe detector 4C1, frequency 2.0-4.0 MHz (Siemens 
Healthcare, Erlangen, Germany) according to routine 
instructions. ARFI was mainly conducted by a radiologist 
(Dong CF) with assistant from another physician and 
a nurse. Dong CF has 11-year experience in clinical 
radiology and 4-year experience in ARFI diagnosis. 
Form of the liver capsule and the echogenicity of hepatic 
parenchyma were recorded. Detection of SWV (m/s) of 
hepatic segments s5, s6, s7 and s8 was repeated for 3 
times and the mean values were calculated. Thus, 12 
measurements of hepatic segments s5, s6, s7, s8 were 
recorded. Our pilot study in healthy volunteers showed 
that when compared with conventional ARFI protocol 
(mean value from 10 measurements), the current pro-
tocol exhibited similar results with smaller standard 
deviation (1.08 ± 0.21 m/s vs 1.11 ± 0.12 m/s; t = 
0.6794, P > 0.05). This is consistent with a report that 
showed the reproducibility of measurements in the right 
lobe was higher[20]. Images and data of ARFI were saved 
for analysis.
Blood markers for APRI and Forns index evaluations
AST was determined in the same laboratory prior to 
the liver biopsy using Siemens ADVIA 2400 Chemistry 
system (Siemens Healthcare). Enzymatic activity was 
measured at 37 ℃, according to International Federation 
of Clinical Chemistry standards. Platelet count was 
assessed by an automatic blood cell analyzer (XE-5000 
Automated Hematology System, Sysmex, Lincolnshire, 
IL). The ULN range of AST was considered as 40 U/L. 
APRI = AST(/ULN)/PLT(109/L) × 100.
Forns index = 7.811 - 3.131 × Ln(PLT) + 0.781 × 
Ln(GGT) + 3.467 × Ln(age) - 0.014 × (cholesterol)
Combined assessments of ARFI + APRI/ARFI + Forns 
index
A logistic regression analysis model for hepatic fibrosis 
≥ F2 has been established by using the ENTER method. 
Statistical analysis
Continuous normal distribution data were represented 
with means ± SD. Categorical normal distribution data 
were represented with median ± quartile (M ± Q). 
Kruskal-Wallis test was used to analyze the differences 
among these different groups. When there was a stati-
stical significance (P < 0.05), a post-hoc Bonferroni test 
was applied to analyze data between two groups. P < 
0.05 was considered to be statistically significant using 
a SPSS 13.0, IBM, Armonk, NY. The box plot was used 
to record the mean and degree of variation. MedCalc 
software (Ostend, Belgium) was used to draw receiver 
operating characteristic curve (ROC) and calculate cut-
off value, sensitivity, specificity, positive predictive 
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ment results of ARFI, APRI, and Forns index of all 
subjects were shown in Table 1. The average ages of 
subjects with significant or serious fibrosis (F2, F3 and 
F4) were significantly higher than subjects with mild 
fibrosis (F1) (P = 0.009 for F2 vs F3, P < 0.001 for F2 
vs F4, and P < 0.001 for F3 vs F4). Also, male patients 
showed higher incidence of hepatic fibrosis (from F1 to 
F4) than female patients. The differences of ARFI results 
among F0, F1, F2, F3 and F4 groups were significant (P 
< 0.05). For Forns index, except for F0 and F1 group, 
the differences among other groups were significant (P 
< 0.05). Results of APRI indicated that only F4 showed 
significant change from other groups (F0, F1, F2 and F3) 
(all P < 0.001), while the F1, F2, and F3 groups showed 
significantly higher values than the F0 group (all P < 
0.001) (Table 1). 
Correlations between ARFI, APRI, Forns index and 
hepatic pathology
The median, quartile, minimum value, maximum value 
and outlier of ARFI, APRI and Forns index were shown in 
box type image (Figure 1). There was a high correlation 
between the staging of ARFI/APRI/Forns index and the 
hepatic histology, with correlation coefficient 0.845 (P 
< 0.001), 0.641 (P < 0.001) and 0.644 (P < 0.001), 
respectively (Table 2). In ENTER model, Y axis was the 
result from liver biopsy and the X axis was the results 
from ARFI + APRI or ARFI + Forns Index combined 
assessments. The equation for ARFI + APRI was y = 
-13.27 + 9.11 ARFI + 5.03 APRI, while the equation for 
ARFI + Forns index was y = -15.08 + 8.67 ARFI + 0.70 
Forns index.
Determination of the cut-off values of hepatic fibrosis 
staging
There were significantly different interval ranges between 
different liver fibrotic stages and the corresponding 
ARFI and APRI results. In order to determine the cut-off 
value of each fibrotic stage, we applied ROC to analyze 
the data from both ARFI and APRI (Figure 2). From the 
result, it showed that the diagnostic performance of ARFI 
for predicting stages more than F2, F3 and F4 was 91% 
(95%CI: AUROC = 0.87-0.95, P < 0.05), 94% (95%CI: 
values, negative predictive values, AUROC of ARFI and 
APRI for every liver fibrotic stage. The ROC curve of two 
variables combination (ARFI + APRI and ARFI + Forns 
index) and three variables combination (ARFI + APRI 
+ Forns index) for significant hepatic fibrosis (≥ F2) 
was also analyzed. When AUROC > 0.5, the closer of 
AUROC to 1, the better diagnostic outcome it provided. 
Comparison of AUROC among these parameters and 
their combination was analyzed by the Delong test[21].
RESULTS
Results of basic information, ARFI, APRI, and Forns 
index
Basic information (e.g., age and gender) and assess-
Table 1  Results of basic information and acoustic radiation force impulse/aspartate aminotransferase to platelet ratio index/Forns 
index of all examinees
Group Age (yr) Gender (male/female) BMI ARFI APRI Forns index
F0 (n = 40)    39.8 ± 11.45   30/10 22.91 ± 2.31 1.09 (1.01, 1.21) 0.19 (0.14, 0.28) 5.58 ± 1.33
F1 (n = 41) 33.07 ± 7.971 33/8 22.37 ± 2.24  1.19 (1.15, 1.28)1  0.34 (0.28, 0.44)1 5.60 ± 1.19
F2 (n = 52) 38.27 ± 7.662 43/9 22.26 ± 2.41    1.31 (1.21, 1.43)1,2  0.42 (0.32, 0.64)1    6.73 ± 1.091,2
F3 (n = 59) 39.83 ± 8.732   47/12 22.44 ± 2.57      1.52 (1.35, 1.64)1,2,3    0.45 (0.32, 0.86)1,2      7.58 ± 1.551,2,3
F4 (n = 54)        43.85 ± 10.811,2,3,4   44/10 22.35 ± 2.47        1.92 (1.74, 2.14)1,2,3,4        0.80 (0.51, 1.68)1,2,3,4        9.43 ± 2.301,2,3,4
χ 2/F     7.907 0.947 0.477 176.043 107.992   49.501
P value < 0.001 0.918 0.753  < 0.001  < 0.001 < 0.001
For age and Forns index, data were represented in mean ± SD. For ARFI and APRI data, results were exhibited in median ± quartile. 1Means significant 
change against the F0 group; 2Means significant change against the F1 group; 3Means significant change against the F2 group; 4Means significant change 
against the F3 group. For gender, ARFI and APRI comparisons, size of test α’ = α/n = 0.005; for age and Forns index comparison, size of test α = 0.05. ARFI: 
Acoustic radiation force impulse; APRI: Aspartate aminotransferase to platelet ratio index; BMI: Body mass index.
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Figure 1  Box plots show correlation between noninvasive tests and 
histological stages from liver biopsy. Top and bottom of boxes represent first 
and third quartiles, respectively. Length of box represents interquartile range 
within which 50% of values are located. Line through each box represents 
median. Error bars mark the minimum and maximum values (range). Small 
circles represent the outliers. Triangles represent the extreme value, which is > 
3 × interquartile range. ARFI: Acoustic radiation force impulse; APRI: Aspartate 
transaminase to platelet ratio index.
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AUROC = 0.90-0.96, P < 0.05), 96% (95%CI: AUROC 
= 0.93-0.98, P < 0.05), and the best cut-off value of F2, 
F3 and F4 was 1.29, 1.43 and 1.62 m/s. However, APRI 
measurement showed decreased accuracy of diagnosing 
significant fibrosis when compared with ARFI (Table 3).
Combined assessment of ARFI + APRI/ARFI + Forns 
index/ARFI + APRI + Forns index for hepatic fibrosis ≥ 
F2
Firstly we established a logistic regression analysis 
model for hepatic fibrosis ≥ F2 in which the Y axis 
was the result from liver biopsy and the X axis was 
the results from combined ARFI + APRI/ARFI + Forns 
index assessment (Table 4). From the AUROC results 
of Table 5, when evaluating patients with hepatic 
fibrosis ≥ F2, there was a significant change between 
the AUROCs of ARFI + APRI and ARFI alone (0.940 
and 0.913, respectively; Z = 2.77, P = 0.006), also 
between ARFI + Forns index and ARFI alone (0.933 
and 0.913, respectively; Z = 2.091, P = 0.037), ARFI + 
APRI + Forns index and ARFI alone (0.944 and 0.913, 
respectively; Z = 2.893, P = 0.004), indicating an 
enhanced screening ability of the combined assessment 
than ARFI alone. However, the change between ARFI + 
APRI and ARFI + APRI + Forns index was not significant 
(0.940 and 0.944, respectively; Z = 0.958, P = 0.338), 
suggesting that Forns index cannot further improve the 
diagnostic accuracy for staging hepatic fibrosis ≥ F2 
when using a combined method of ARFI + APRI (Figure 
3).
DISCUSSION
To date, the gold standard for the diagnosis of liver 
fibrosis remains to be liver biopsy. In most circum-
stances, patients find it difficult to accept liver biopsy due 
Table 2  Correlations of non-invasive tests with histological fibrosis stage by rank correlation analysis
Histological staging Noninvasive test Correlation (Spearman coefficient) 95%CI P  value
METAVIR classification ARFI 0.845 0.805-0.877 < 0.001
APRI 0.641 0.561-0.709 < 0.001
Forns index 0.644 0.564-0.711 < 0.001
ARFI: Acoustic radiation force impulse; APRI: Aspartate aminotransferase to platelet ratio index. 
Table 3  Cut-off values of acoustic radiation force impulse and aspartate aminotransferase to platelet ratio 
index for the diagnosis of liver fibrosis (95%CI)
≥ F1 ≥ F2 ≥ F3 F4
ARFI
   Cut-off (m/s) 1.26 1.29 1.43 1.62
   Sensitivity 76.2% (69.80-81.90) 83.6% (77.10-88.90) 82.3% (74.00-88.80) 90.7% (79.70-96.90)
   Specificity 95.0% (83.10-99.40) 90.1% (89.50-97.60) 89.5% (83.00-94.10) 92.2% (87.40-95.60)
   PPV 99.1% (96.20-99.90) 94.5% (91.90-99.10) 86.9% (79.10-92.70) 76.0% (64.40-86.30)
   NPV 35.9% (22.50-47.40) 73.0% (63.10-81.40) 85.6% (78.60-91.00) 97.2% (93.70-99.10)
   AUROC  0.90 (0.86-0.94)a  0.91 (0.87-0.95)a  0.94 (0.90-0.96)a  0.96 (0.93-0.98)a
APRI
   Cut-off (m/s) 0.30 0.41 0.49 0.44
   Sensitivity 84.0% (78.20-88.70) 68.5% (60.80-75.50) 63.7% (54.10-72.60) 83.3% (70.70-92.10)
   Specificity 85.0% (70.20-94.30) 82.7% (72.70-90.20) 79.7% (71.90-86.20) 67.2% (70.10-73.80)
   PPV 97.6% (94.20-99.30) 89.0% (82.20-93.80) 72.8% (62.90-81.20) 41.7% (32.30-51.60)
   NPV 42.7% (30.00-56.10) 56.3% (46.80-65.40) 72.1% (64.00-79.20) 93.5% (87.90-97.00)
   AUROC  0.92 (0.88-0.95)a  0.84 (0.79-0.89)a  0.79 (0.73-0.84)a  0.82 (0.76-0.86)a
aP < 0.05 for all values. ARFI: Acoustic radiation force impulse; APRI: Aspartate aminotransferase to platelet ratio index; 
AUCROC: Area under the receiver operating characteristic curve; NPV: Negative predictive value; PPV: Positive predictive value.
Table 4  Binary logistic regression of two variables in hepatic fibrosis ≥ F2
Combination Variable RC SD of RC Wald P  value OR 95%CI of OR
ARFI + APRI ARFI    9.11 1.48 37.68 < 0.001 9085.54       494.92-166789.07
APRI    5.03 1.30 15.07 < 0.001   153.01     12.07-1939.04
Constant -13.27 1.95 46.09 < 0.001 - -
ARFI + Forns index ARFI    8.67 1.44 36.16 < 0.001 5824.00     345.12-98280.97
Forns index    0.70 0.17 16.27 < 0.001       2.01 1.43-2.82
Constant -15.08 2.08 52.68 < 0.001 - -
ARFI: Acoustic radiation force impulse; APRI: Aspartate aminotransferase to platelet ratio index; OR: Odds ratio; RC: Regression 
coefficient.
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to its complications. From 2009, with the introduction of 
ARFI, the clinical research on non-invasive assessment 
of fibrosis rapidly progressed. As an advanced imaging 
technology, ARFI is capable of providing biomechanical 
information on the tissue stiffness and elasticity using 
conventional ultrasound scanning of anatomical location 
and structure[22,23]. However, its utility, particularly in 
combination with other non-invasive methods in hepa-
titis B, has not been adequately evaluated.
In the current study, CHB patients with different 
stages of liver fibrosis were diagnosed by ARFI, APRI, 
Forns index and their combined assessments. Our 
results demonstrated that the mean SWV value from 
ARFI was highly correlated with the staging of liver 
fibrosis classified by liver biopsy (METAVIR classification). 
This result indicated that biomechanical properties 
(e.g., hepatic elasticity and stiffness) had progressed 
from liver fibrosis to cirrhosis during the development 
of CHB, which was consistent with the pathological 
progression of hepatocyte degeneration, necrosis, inflam-
mation reaction, hepatocyte regeneration, formation 
of connective tissue fiber intervals, and liver lobule 
structural failure during the course of liver fibrosis of 
HBV infection[24].
With the progression of liver fibrosis from F2 to 
F4, the effectiveness of ARFI on the diagnosis of liver 
fibrosis also increased. That is, when the value of SWV 
was lower than 1.29 m/s (clinically F0 and F1 patients), 
hepatic fibrosis could be unlikely significant. SWV 
higher than 1.43 m/s could be likely considered as an 
indication for serious liver fibrosis (F3, sensitivity 82.3% 
and specificity 89.5%), and SWV > 1.62 m/s could be 
diagnosed as early cirrhosis (F4, sensitivity 90.7% and 
specificity 92.2%). In addition, when they were used 
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Figure 2  Receiver operating characteristic curves for acoustic radiation force impulse and aspartate transaminase to platelet ratio index for diagnosis of 
hepatic fibrosis (F1-F4). ARFI: Acoustic radiation force impulse; APRI: Aspartate transaminase to platelet ratio index.
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independently, ARFI was the best way for the diagnosis 
of fibrosis ≥ F2; ARFI provides a dynamic technical 
support for non-invasive diagnosis of liver fibrosis. This 
result is in line with a report found that ARFI correlated 
well with liver biopsy and thus was a reliable ultrasound-
based method for the assessment of advanced fibrosis 
induced by CHB[25].
Currently it is difficult for non-invasive diagnostic 
methods to differentiate F0 and F1 fibrotic stages. 
However, in this study, we found that there was a signi-
ficant change of ARFI readings between the F0 and 
F1 groups (Table 1). It is known that stage F2 posse-
sses significant diagnostic value in determining the 
progression of liver disease and anti-viral therapy choice. 
At this stage, patients have more risk in developing 
complications such as portal hypertension, cirrhosis, and 
HCC than patients without significant liver fibrosis[26]. 
If patients receive anti-viral therapy promptly during 
this period, it is possible to retard or even reverse 
the pathological progression of fibrosis[27]. Thus, early 
accurate diagnosis and appropriate therapy to patients 
at F2 fibrosis evidently decreases the morbidity and 
mortality of patients with CHB[28,29].
Similar to the FibroScan method which is partially 
affected by obesity[30], ARFI also has some disad-
vantages. For example, certain hepatic disorders (e.g., 
ascites and acute icteric hepatitis) may affect the 
ARFI results. However, in our study, all the enrolled 
subjects including obese patients with BMI of 30.81 
successfully got SWV values. Thus, ARFI may have a 
wider application range than FibroScan. In general, ARFI 
overcome a spectrum of disadvantages of conventional 
ultrasound technologies, such as no manual operation 
of pressing, improved depth limitation (5 cm of the 
earlier machines and 8 cm of the newer machines) 
and location of imaging. Compared to other methods, 
ARFI has no pain, with good reproducibility of data and 
simple operation. Indeed, ARFI is potentially limited by 
patients with a BMI > 40 or after contrast-enhanced 
ultrasonography. Thus, its combination with other non-
invasive methods is necessary to enhance the diagnostic 
accuracy[31].
Currently, serological diagnostic assays for non-
invasive assessment of liver fibrosis are available in-
cluding direct and indirect methods. The main purpose 
of these methods is to identify the existence of fibrosis 
but not the grading or staging. In this study, APRI and 
Forns index were also used to stage liver fibrotic stage. 
Although the sensitivity and specificity of these methods 
for the diagnosis of liver fibrosis was lower than ARFI, 
Table 5  Comparing area under the receiver operating characteristic curve of acoustic radiation 
force impulse/acoustic radiation force impulse + aspartate aminotransferase to platelet ratio 
index/acoustic radiation force impulse + Forns index/acoustic radiation force impulse + aspartate 
aminotransferase to platelet ratio index + Forns index in patients with fibrosis stage ≥ F2
Comparison AUROC Difference 95%CI Z P  value
Lower limit Upper limit
ARFI 0.913 0.027  0.008 0.046 2.770 0.006
ARFI + APRI 0.940
ARFI 0.913 0.020  0.001 0.040 2.091 0.037
ARFI + Forns index 0.933
ARFI 0.913 0.031  0.010 0.053 2.893 0.004
ARFI + APRI + Forns index 0.944
ARFI + APRI 0.940 0.007 -0.011 0.025 0.728 0.466
ARFI + Forns index 0.933
ARFI + APRI 0.940 0.005 -0.005 0.014 0.958 0.338
ARFI + APRI + Forns index 0.944
ARFI + Forns index 0.933 0.011 -0.001 0.023 1.789 0.074
ARFI + APRI + Forns index 0.944
AUROC: Area under the receiver operating characteristic curve; ARFI: Acoustic radiation force impulse; APRI: 
Aspartate aminotransferase to platelet ratio index.
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Figure 3  Receiver operating characteristic curves of acoustic radiation 
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platelet ratio index.
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they partially reflected the pro-inflammatory response 
and hepatic compensation. The most important finding 
of this study was that combined measurement of ARFI 
and APRI exhibited better accuracy than ARFI or APRI 
alone when evaluating ≥ F2 fibrosis stage. Combination 
of ARFI, APRI and Forns index did not further improve 
the diagnostic effect than the combination of ARFI and 
APRI. 
In conclusion, ARFI, APRI and Forns index correlated 
well with the histological liver fibrosis stages in CHB 
patients. ARFI showed better accuracy than APRI when 
evaluating F2, F3 and F4 stages. Combined check with 
ARFI and APRI showed a significant enhancement of 
diagnostic accuracy than ARFI or APRI alone. ARFI 
+ APRI exhibited similar enhancement of diagnostic 
accuracy of hepatic fibrosis with ARFI + APRI + Forns 
index when evaluating fibrotic stages more than F2 
in CHB patients. This study provides an ideal and con-
venient non-invasive diagnostic method for the detection 
of hepatic fibrosis of CHB patients in clinical practice.
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the assessment of liver fibrosis in CHB. The authors found that ARFI + APRI 
exhibited similar enhancement of diagnostic accuracy of hepatic fibrosis with 
ARFI + APRI + Forns index when evaluating fibrotic stages more than F2 in 
CHB patients.
Applications
The data in this study suggest that doctor can yield favorable outcomes through 
the accumulation of technical experience. Furthermore, this study also provides 
readers with important information regarding an ideal and convenient non-
invasive diagnostic method for the grading of hepatic fibrosis of CHB patients.
Terminology
ARFI imaging involves mechanically exciting a localized region of interest in the 
tissue with acoustic radiation force to induce a shear wave in the tissue. The 
displacement of the shear wave is tracked using a pulse-echo mode ultrasound 
at several lateral locations along the propagation path of the shear wave. By 
measuring the time to peak displacement at each location, the shear wave 
velocity was calculated, which is directly related to the elasticity of the tissue. 
APRI = AST(/ULN)/PLT(109/L) × 100. Forns index = 7.811 - 3.131 × Ln(PLT) + 
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